Evaluating the applicability of ivabradine in acute heart failure.

ABSTRACT:

Background

While ivabradine has demonstrated benefits in heart rate control and prognosis for chronic heart failure patients, its application in acute decompensated heart failure remains underexplored.

Hypothesis

For patients with acute decompensated heart failure with reduced ejection fraction (HFrEF) who are intolerant to β-blockers or unable to further titrate their dosage, the use of ivabradine is hypothesized to be effective and safe is improving outcomes.

Methods

This retrospective, multicenter database analysis included patients with hospitalized decompensated heart failure with a left ventricular ejection fraction of ≤40% from June 1, 2015 to December 31, 2020. The exclusion criteria were a baseline heart rate of <70 bpm, previous use of ivabradine, mortality

SUBMITTER: Tsai TH 

PROVIDER: S-EPMC10765997 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature